Skip to main content

Table 2 Characteristics of PSA patients in qPCR validation stage

From: Comprehensive analyses of long non-coding RNA expression profiles by RNA sequencing and exploration of their potency as biomarkers in psoriatic arthritis patients

Parameters

PSA patients (N = 93)

Age (years)

52.2 ± 14.7

Gender (n/%)

 Male

60 (64.5)

 Female

33 (35.5)

Family history of PSA (n/%)

 Yes

21 (22.6)

 No

72 (77.4)

Disease duration of psoriasis (years)

12 (6–24)

Disease duration of arthritis (years)

3 (1–7)

Psoriasis subtype (n/%)

 Vulgaris

85 (91.4)

 Others

8 (8.6)

Arthritis subtype (n/%)

 Peripheral

72 (77.4)

 Axial

13 (14.0)

 Mixed

8 (8.6)

Affected BSA (%)

18.9 ± 7.4

PASI score

7.0 ± 2.8

CRP (mg/l)

1.9 (0.5–10.8)

ESR (mm/h)

18 (8–39)

SJC (joints)

2 (1–4)

TJC (joints)

3 (1–6)

Pain VAS score

5.0 ± 2.6

PGA score

5.1 ± 1.4

  1. Data were presented as mean value±standard deviation, median value (25th–75th quantile) or count (percentage). PSA Psoriatic arthritis, qPCR, quantitative polymerase chain reaction, BSA, Body surface area, PASI Psoriasis area and severity index, CRP C-reactive protein, ESR Erythrocyte sedimentation rate, SJC Swollen joint count, TJC Tender joint count, VAS Visual analogue scale, PGA Patients’ global assessment